Match!
Jasgit C. Sachdev
Translational Genomics Research Institute
CancerPathologyImmunologyCancer researchMedicine
112Publications
18H-index
1,324Citations
What is this?
Publications 110
Newest
#2Natasha Woodward (UQ: University of Queensland)H-Index: 5
Last. Christine K. Ratajczak (AbbVie)H-Index: 4
view all 11 authors...
ABBV-176 is an antibody-drug conjugate composed of the humanized antibody h16f (PR-1594804) conjugated to a highly potent, cytotoxic cross-linking pyrrolobenzodiazepine dimer (PBD; SGD-1882) targeting the prolactin receptor (PRLR), which is overexpressed in several solid tumor types. This phase 1, dose-escalation study (NCT03145909) evaluated the safety, pharmacokinetics, and preliminary activity of ABBV-176 in patients with advanced solid tumors likely to exhibit elevated levels of PRLR. Patien...
Source
#1Erika Paige Hamilton (Sarah Cannon Research Institute)H-Index: 21
#2Manish R. Patel (Sarah Cannon Research Institute)H-Index: 28
Last. Elizabeth BuckH-Index: 12
view all 14 authors...
TPS3665Background: A significant unmet need exists for drugs targeting allosteric ErbB mutations (non-canonical mutations outside the ATP binding site). Current EGFR and HER2 tyrosine kinase inhibi...
Source
#2Pamela N. Munster (UCSF: University of California, San Francisco)H-Index: 49
Last. Stacie Peacock ShepherdH-Index: 11
view all 6 authors...
Source
#1Devalingam Mahalingam (NU: Northwestern University)H-Index: 27
#2Manish R. Patel (Sarah Cannon Research Institute)H-Index: 28
Last. Floris A. de Jong (Takeda Pharmaceutical Company)H-Index: 1
view all 11 authors...
AIM: Preclinical evidence suggests that oxidized macrophage migration inhibitory factor (oxMIF) may be involved in carcinogenesis. This phase 1 study (NCT01765790) assessed safety, tolerability, pharmacokinetics and antitumor activity of imalumab, an oxidized macrophage migration inhibitory factor (oxMIF) inhibitor, in patients with advanced cancer using '3+3' dose-escalation. METHODS: In Schedule 1, patients with solid tumors received doses from 1-50 mg/kg IV every two weeks. In Schedule 2, pat...
1 CitationsSource
#1David K. Hong (University of Texas MD Anderson Cancer Center)H-Index: 59
#2Yoon-Koo Kang (Asan Medical Center)H-Index: 54
Last. Tae Won Kim (Seoul National University Hospital)H-Index: 74
view all 23 authors...
In this first-in-human, Phase 1 study of a microRNA-based cancer therapy, the recommended Phase 2 dose (RP2D) of MRX34, a liposomal mimic of microRNA-34a (miR-34a), was determined and evaluated in patients with advanced solid tumours. Adults with various solid tumours refractory to standard treatments were enrolled in 3 + 3 dose-escalation cohorts and, following RP2D determination, expansion cohorts. MRX34, with oral dexamethasone premedication, was given intravenously daily for 5 days in 3-week...
4 CitationsSource
#1Rebecca C. Arend (UAB: University of Alabama at Birmingham)H-Index: 16
#2Cesar M. Castro (Harvard University)H-Index: 21
Last. Adam C. ElNaggar (UT: University of Tennessee)H-Index: 7
view all 18 authors...
#1Ruth O'Regan (UW: University of Wisconsin-Madison)H-Index: 14
#2Randolph Hurley (HealthPartners)H-Index: 1
Last. Arkadiusz Z. Dudek (HealthPartners)H-Index: 4
view all 8 authors...
Background: TTC-352 is a selective human ER partial agonist (ShERPA) developed for treatment of ER+ breast cancer (BC). ShERPAs mimic the effects of estradiol (E2) in hormone-independent, endocrine-resistant BC cells, but since it has only partial agonist activity in ER+ cells, it could have an improved side effect profile. Thus, TTC-352 could be a promising option for endocrine-resistant BC. Methods: This is an open-label, accelerated dose escalation study with primary endpoint of maximum toler...
Source
#1Sarina Anne Piha-Paul (University of Texas MD Anderson Cancer Center)H-Index: 36
#2Jasgit C. Sachdev (TGen: Translational Genomics Research Institute)H-Index: 18
Last. Bert H. O'Neil (IU: Indiana University)H-Index: 27
view all 15 authors...
Purpose: Bromodomain and extraterminal (BET) proteins play important roles in transcriptional regulation relevant to cancer pathogenesis, and therapeutic targeting/inhibition of BET causes apoptosis of cancer cells in vitro. In this first-in-human study of the pan-BET inhibitor mivebresib (ABBV-075), the safety profile, MTD, and recommended phase II dose (RP2D) were determined in patients with advanced solid tumors. Experimental Design: A 3 + 3 dose escalation for different mivebresib dosing sch...
7 CitationsSource
#1Zev A. Wainberg (UCLA: University of California, Los Angeles)H-Index: 32
#2Jasgit C. SachdevH-Index: 18
Last. Patricia LoRusso (Yale Cancer Center)H-Index: 64
view all 11 authors...
Source
#1Rebecca C. Arend (UAB: University of Alabama at Birmingham)H-Index: 16
#2Cesar M. Castro (Harvard University)H-Index: 21
Last. Michael J. BirrerH-Index: 86
view all 17 authors...
Objectives Wnt/β-catenin signaling is frequently dysregulated in gynecologic malignancies. CTNNB1, APC and RNF43 mutations cause pathway activation; CTNNB1 stabilizing mutations lead to elevated DKK1 expression which promotes an immune suppressive tumor microenvironment. Neutralization by DKN-01 (D), a mAb against DKK1, is being tested in a phase 2 basket study. Methods Eligibility included recurrent endometrial cancer (EC) or platinum resistant/refractory ovarian cancer (OC) enriched (∼50%) for...
Source
12345678910